Last reviewed · How we verify
Metal Panel T.R.U.E. Test
Metal Panel T.R.U.E. Test is a Biologic drug developed by Allerderm. It is currently in Phase 3 development for Diagnosis of contact allergy to metals (nickel, cobalt, chromium, and other metal allergens).
Metal Panel T.R.U.E. Test is a diagnostic patch test system that identifies contact allergies to metals by measuring delayed-type hypersensitivity reactions.
The Metal Panel T.R.U.E. Test is a small molecule intervention used to study conditions such as Atopic Dermatitis Eczema. It is being evaluated in a clinical study (NCT04500834) to assess its safety and efficacy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Metal Panel T.R.U.E. Test |
|---|---|
| Sponsor | Allerderm |
| Modality | Biologic |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
The test applies standardized metal allergen patches to the skin and monitors for allergic contact dermatitis reactions over several days. It helps clinicians diagnose metal sensitivities (such as nickel, cobalt, and chromium) by reproducing and observing the immune response in a controlled manner. This is a diagnostic tool rather than a therapeutic agent.
Approved indications
- Diagnosis of contact allergy to metals (nickel, cobalt, chromium, and other metal allergens)
Common side effects
- Local skin irritation at patch site
- Allergic contact dermatitis reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metal Panel T.R.U.E. Test CI brief — competitive landscape report
- Metal Panel T.R.U.E. Test updates RSS · CI watch RSS
- Allerderm portfolio CI
Frequently asked questions about Metal Panel T.R.U.E. Test
What is Metal Panel T.R.U.E. Test?
How does Metal Panel T.R.U.E. Test work?
What is Metal Panel T.R.U.E. Test used for?
Who makes Metal Panel T.R.U.E. Test?
What development phase is Metal Panel T.R.U.E. Test in?
What are the side effects of Metal Panel T.R.U.E. Test?
Related
- Manufacturer: Allerderm — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Diagnosis of contact allergy to metals (nickel, cobalt, chromium, and other metal allergens)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing